*ST赛隆两月内再迎高层变动：董事长等3人辞职，人事动荡叠加业绩压力引关注

Core Viewpoint - The recent personnel changes at Sairong Pharmaceutical have raised concerns among investors, especially following the company's poor financial performance and ongoing delisting risk due to negative net profit and low revenue [1][4]. Group 1: Personnel Changes - Sairong Pharmaceutical announced the resignation of key executives, including Chairman Chen Ke and Vice Presidents Zhang Xu and Duan Daifeng, with Chen continuing as President [2]. - This marks the second significant personnel shift within two months, following a complete board resignation due to a change in control [2][3]. - The new controlling shareholder, Hainan Yayi, has no actual controller, leading to further uncertainty in management stability [3]. Group 2: Financial Performance - In the first half of the year, Sairong Pharmaceutical reported revenue of 136 million yuan and a net loss of 14.83 million yuan, a significant decline from the previous year [1][4]. - The company faces delisting risk as it is projected to have negative net profit and revenue below 300 million yuan for the 2024 fiscal year [4]. - Sairong operates in the pharmaceutical industry, focusing on drug manufacturing and AI server business, with the latter still in its early stages [4]. Group 3: Business Operations - The company’s main business segments include pharmaceutical manufacturing, with products like Tigecycline and Agatroban, and an emerging AI server business [4]. - Sairong emphasizes the need to adapt to market competition and regulatory changes, particularly in drug procurement policies [5]. - The management plans to enhance research capabilities and optimize project selection for new drug development [5].